Literature DB >> 30988578

Upfront Lenalidomide in Follicular Lymphoma: Time has Come or Not?

Vikas Garg1, Ajay Gogia1, Gopila Gupta2.   

Abstract

Entities:  

Year:  2018        PMID： 30988578      PMCID： PMC6439029          DOI： 10.1007/s12288-018-1046-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  4 in total

1.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

2.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

3.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

4.  Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Authors:  Franck Morschhauser; Nathan H Fowler; Pierre Feugier; Reda Bouabdallah; Hervé Tilly; M Lia Palomba; Christophe Fruchart; Edward N Libby; Rene-Olivier Casasnovas; Ian W Flinn; Corinne Haioun; Hervé Maisonneuve; Loic Ysebaert; Nancy L Bartlett; Kamal Bouabdallah; Pauline Brice; Vincent Ribrag; Nicolas Daguindau; Steven Le Gouill; Gian M Pica; Alejandro Martin Garcia-Sancho; Armando López-Guillermo; Jean-François Larouche; Kiyoshi Ando; Maria Gomes da Silva; Marc André; Pierre Zachée; Laurie H Sehn; Kensei Tobinai; Guillaume Cartron; David Liu; Jianming Wang; Luc Xerri; Gilles A Salles
Journal:  N Engl J Med       Date:  2018-09-06       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.